Pfizer, Takeda and BB Biotech invested a combined $88m in the offering, conducted less than five months after Myovant spun out of Roivant Sciences.
Myovant Sciences, a US-based women’s health spinout of biopharmaceutical company Roivant Sciences, raised approximately $218m yesterday in an initial public offering that included investments by pharmaceutical firms Takeda and Pfizer.
The company issued 14.5 million shares priced at $15.00 each in what was the biggest biotech IPO of 2016 so far.
Underwriters Citigroup Global Markets, Cowen and Company, Evercore Group, Barclays Capital, JMP Securities and Robert W. Baird have a 30-day option to buy almost 2.2 million additional shares, lifting…
